MedPath

Comparison of Neostigmine versus Sugammadex after muscle paralysis by muscle relaxants by doing ultrasonography of diaphragm.

Not Applicable
Not yet recruiting
Conditions
Health Condition 1: O- Medical and Surgical
Registration Number
CTRI/2023/05/052678
Lead Sponsor
Dr Prasanta Kumar Das
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patients undergoing elective non-cardiac

surgery

2.ASA grade I to III

3.AGE- 18- 70 Years

Exclusion Criteria

1.Emergency surgery

2.Refusal to treatment

3.Allergy to study drug

4.Renal and hepatic failure

5.Pregnant and nursing mother

6.Diaphragmatic palsy

7.Poor image quality

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the incidence of PORC defined by diaphragmatic thickening fraction â?¤0.36 , <br/ ><br>between two groups after administration of Neostigmine or Sugammadex assessed by diaphragm USG <br/ ><br>Timepoint: We will measure the thickening fraction of diaphragm by ultrasonography at three readings. The baseline will be taken before induction, just before extubation, at 30 minutes after extubation in postop area. <br/ ><br>All the outcomes will be assessed for 24 hours for taking the results into account. <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
To compare: <br/ ><br> <br/ ><br>1)Time to achieve TOF ratio â?¥ 0.9 or four twitches since administration of last dose of muscle relaxant (whichever is later) <br/ ><br> <br/ ><br>2)Time to achieve TOF ratio â?¥ 0.9 or four twitches after administration of reversal agent (whichever is later) <br/ ><br> <br/ ><br>3)Postoperative pulmonary complications (PPC) within 24 hours [ PPC defined by SpO2 less than 90% or requiring oxygen therapy to maintain SpO2 more than 95% ] <br/ ><br> <br/ ><br>3)Incidence of adverse effects <br/ ><br>Timepoint: within 24 hours
© Copyright 2025. All Rights Reserved by MedPath